Capricor Therapeutics signed a lease for a new 171,000-square-foot headquarters in San Diego, including expanded manufacturing cleanrooms, R&D labs, and offices. The initial monthly rent is about $958,000 with 3% annual increases, but the company receives an 18-month full rent abatement and a six-month partial abatement. The lease term begins when an FDA approval condition for Deramiocel is met or by Dec 31, 2026, whichever comes first, and rent starts 12 months later. If FDA approval does not occur by year-end, either party can terminate the lease.

View Full Filing (SEC EDGAR)

View all Form 8-K filings

FAQ

Who are the top institutional investors holding CAPRICOR THERAPEUTICS INC (CAPR)?

Major stakeholders currently include Suvretta Capital Management, LLC ($116.1M), BlackRock, Inc. ($104.0M), Tang Capital Management LLC ($103.4M). Based on the latest 13F filings, there are a total of 181 tracked investment funds and institutions maintaining positions in CAPR.

What is the overall institutional sentiment toward CAPR recently?

Institutional sentiment appears Bullish (Net Buying). During the most recent reporting quarter, the stock experienced a net inflow of $190.3M, driven by 125 managers accumulating shares while 58 reduced their exposure.

Which institutions have been selling or reducing their CAPR positions?

In the latest period, 37 funds trimmed their holdings, and 21 managers completely exited their positions. The aggregate reported sell value was $467.6M.

Are there any notable investors adding CAPR to their portfolios?

Yes, buying activity remains notable. 64 institutions opened new positions in {ticker}, and 61 existing holders added to their shares. The total reported buy value for the quarter amounted to $741.2M.